Home / News & Announcement / Recent Advancement in Cancer Molecular Signaling
Recent Advancement in Cancer Molecular Signaling

It is well-known in clinics that different oncological subjects respond differently to the same drug, due to the wide number of specific gene sequence of proteins involved in the response to drug therapy. This area is further complicated by the fact that most genes have different statutary and epigenomic characteristics in different individuals. The study of this discipline not only is constantly unveiling specific molecular signaling which the onset and progression of cancer can be advocate for, but also offer the tremendous opportunity for a pharmacogenomics-driven specific approach. With the advancement and affordability of new generation sequencing and molecular signaling monitoring, an ever increasing number of cancer pathways are nowadays under scrutiny. At the same time, the study of polymorphic variants of genes responsible for the metabolism, transport, absorption, distribution and excretion of the drugs, is helping zooming down to define sinest regulatory mechanisms based on which to design putative modulators. This holds true also to delineate genes and their isoform regulation of enzymes responsible for the metabolism of many commonly prescribed cancer drugs so to calculate, foresee and ideally prevent major side effects of a given compound.

 

In the present special issue, we welcome researchers actively working in this area, to submit their most recent and relevant findings aiming to the quest of an ever improving cancer understanding and approach. For all of them, BIOCELL does represent an ideal platform to present their data with relevant visibility and trigger fruitful scientific discussion.


Share Link

WeChat scan